First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your lung cancer has been confirmed as metastatic NSCLC
- Your tumor test shows an EGFR mutation like exon 19 deletion or L858R (other specific mutations may also qualify if a common one is present)
- You have not taken an EGFR-targeted pill (EGFR TKI) before
- You must be able to swallow pills and have enough blood counts and organ function for treatment
- You should not have certain serious lung inflammation, major uncontrolled heart issues, or active hepatitis infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
This trial tests a combination of three targeted drugs (osimertinib, cetuximab, and tucatinib) for people with EGFR-mutant lung cancer that has gotten worse after osimertinib. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Metastatic Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.